News Daily News New ACC/AHA Hypertension Guidelines Still Urge Early Treatment but With Some Twists Yael L. Maxwell August 14, 2025
News Daily News PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors Michael O'Riordan July 18, 2025
News Daily News Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION Michael O'Riordan June 04, 2025
News Daily News Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention Michael O'Riordan May 07, 2025
News Daily News REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF Michael O'Riordan March 11, 2025
News Daily News Coverage and Use of Impella and Watchman: A Tale of Four Countries Michael O'Riordan March 04, 2025
News Daily News AHA Stats Show CV Health of Americans Remains Dire Michael O'Riordan January 28, 2025
News Daily News Aspirin Use for Primary Prevention Declining in US: NHANES Michael O'Riordan January 24, 2025
News Daily News New Guidelines for CV Care in Patients Undergoing Noncardiac Surgery Michael O'Riordan September 24, 2024
News Daily News AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients Michael O'Riordan August 26, 2024
News Daily News PREVENT Risk Calculator Means Fewer Patients on Statins, Antihypertensives Michael O'Riordan August 02, 2024
News Daily News Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF Michael O'Riordan July 09, 2024
News Daily News Think You Need a Statin? AHA’s Risk Calculator May Disagree Michael O'Riordan June 28, 2024
News Daily News Excess ApoB Linked to Increased MI, ASCVD Risk in Adults Michael O'Riordan June 04, 2024
News Daily News Statins Effective For Primary Prevention in Old and Very Old Michael O'Riordan May 29, 2024
News Daily News New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise Yael L. Maxwell May 08, 2024
News Daily News Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift Yael L. Maxwell May 03, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024